CLINICAL_TRIALS
trial_result
· 2023-01-26
Clinical Trial Update: Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors [Phase 2]
Summary
Phase 2 trial evaluating brigatinib after treatment with next-generation ALK inhibitors in non-small cell lung cancer has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Criterium, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-01-26